Full Text View
Tabular View
No Study Results Posted
Related Studies
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion (PRIORITY)
This study has been completed.
Study NCT00418483   Information provided by Grifols Therapeutics Inc.

First Received on January 2, 2007.   Last Updated on July 8, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Arterial Occlusive Diseases
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Plasmin (Human) 25 mg
Plasmin (Human) 50 mg
Plasmin (Human) 75 mg
Plasmin (Human) 100 mg
Plasmin (Human) 125 mg
Plasmin (Human) 150 mg
Plasmin (Human) 175 mg
Additional drug interventions recognized in this trial
Fibrinolysin
More general drug interventions related to this trial
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Grifols Therapeutics Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services